Tris lipidation--a novel drug delivery system that alters biodistribution
Tris-lipidation uses Tris to produce drug-fatty acyl conjugates. Radiolabelled Tris-fatty acyl conjugates of methotrexate (MTX) were examined in biodistribution studies in BALB/c mice. Following delivery via a variety of routes, the Tris-lipidated compounds demonstrated features in common with other colloid drug delivery systems. Tissues of the reticuloendothelial system localised the drug following intravenous administration, and the compounds showed prolongation at the site of injection into muscle or fatty tissue, subcutaneously or when inhaled. These findings indicate that the Tris-lipidation platform could be classed as an alternative colloid drug delivery system.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2002 |
|---|---|
| Erschienen: |
2002 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of drug targeting - 10(2002), 6 vom: 28. Sept., Seite 479-87 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Walker, Catherine [VerfasserIn] |
|---|
| Themen: |
023C2WHX2V |
|---|
| Anmerkungen: |
Date Completed 16.04.2003 Date Revised 06.11.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM123531853 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM123531853 | ||
| 003 | DE-627 | ||
| 005 | 20231222201551.0 | ||
| 007 | tu | ||
| 008 | 231222s2002 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0412.xml |
| 035 | |a (DE-627)NLM123531853 | ||
| 035 | |a (NLM)12575738 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Walker, Catherine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tris lipidation--a novel drug delivery system that alters biodistribution |
| 264 | 1 | |c 2002 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2003 | ||
| 500 | |a Date Revised 06.11.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Tris-lipidation uses Tris to produce drug-fatty acyl conjugates. Radiolabelled Tris-fatty acyl conjugates of methotrexate (MTX) were examined in biodistribution studies in BALB/c mice. Following delivery via a variety of routes, the Tris-lipidated compounds demonstrated features in common with other colloid drug delivery systems. Tissues of the reticuloendothelial system localised the drug following intravenous administration, and the compounds showed prolongation at the site of injection into muscle or fatty tissue, subcutaneously or when inhaled. These findings indicate that the Tris-lipidation platform could be classed as an alternative colloid drug delivery system | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Colloids |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Tromethamine |2 NLM | |
| 650 | 7 | |a 023C2WHX2V |2 NLM | |
| 700 | 1 | |a Fraser, Julie M |e verfasserin |4 aut | |
| 700 | 1 | |a Walton, Clayton E |e verfasserin |4 aut | |
| 700 | 1 | |a Widmer, Fred |e verfasserin |4 aut | |
| 700 | 1 | |a Francis, Craig L |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a O'Sullivan, Maree |e verfasserin |4 aut | |
| 700 | 1 | |a Whittaker, Robert G |e verfasserin |4 aut | |
| 700 | 1 | |a Wells, Xanthe E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d 1996 |g 10(2002), 6 vom: 28. Sept., Seite 479-87 |w (DE-627)NLM074733958 |x 1029-2330 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2002 |g number:6 |g day:28 |g month:09 |g pages:479-87 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2002 |e 6 |b 28 |c 09 |h 479-87 | ||